Related Experiment Video
Updated: Sep 14, 2025

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Systematic Review on Clinical Trial Regulations: Perspectives from India, USA, and Europe
Simran Dixit1, Navneet Sharma1, Vikesh Kumar Shukla1
1Amity Institute of Pharmacy, Amity University, Noida, Uttar Pradesh, 201303, India.
Introduction:
The pharmaceutical industry has undergone significant regulatory evolution, particularly in India, with the replacement of Schedule Y by the New Drugs and Clinical Trial (NDCT) Rules. These changes reflect India's commitment to ensuring the efficacy, safety, and quality of drugs while aligning with global standards.
Methods:
To conduct the literature search for the review, we employed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) approach from 2013 to 2024 for selecting titles and abstracts. The following keywords were used: Clinical Trial Regulations, CDSCO, FDA, and EMA. Further, the databases, such as Medline, PubMed, Embase, and Scopus, were explored for the searches.
Results:
The clinical trial framework of India, overseen by the Central Drugs Standard Control Organization (CDSCO), emphasizes expedited approval pathways, ethical oversight by Institutional Ethics Committees (IECs), and cost-effectiveness. Its large and diverse patient pool, along with adherence to Good Clinical Practice (GCP) standards, makes it attractive for multinational trials. Regulatory reforms, such as mandatory trial registration and digital initiatives, further enhance transparency and efficiency.
Discussion:
While India shares common ground with the USA and Europe on many regulatory aspects, it stands out for its efficient processes and accessibility, positioning itself as a key hub for global clinical research. Comparisons reveal India's focus on improving efficiency through digitalization and continuous reforms, underscoring its role in advancing clinical trial practices worldwide.
Conclusion:
The regulatory evolution of India demonstrates a strong commitment to medical innovation, patient safety, and ethical standards, positioning it as a competitive player in global clinical research. Ongoing collaboration among industry, academia, and regulatory bodies is crucial for addressing emerging challenges and promoting a harmonized, patient-centric approach to clinical trials.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Drug Regulation
Preclinical Development: Overview
Drug Control Governance: Regulatory Bodies and Their Impact
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...

